Journal of the American Society of Echocardiography
Volume 22, Issue 10 , Pages 1100-1108 , October 2009

The Cardiac Manifestations of Antiphospholipid Syndrome and Their Echocardiographic Recognition

  • Jeffrey J. Silbiger, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Jeffrey J. Silbiger, MD, Department of Cardiology, Echocardiography Laboratory, Mount Sinai Services at Elmhurst Hospital Center, Mount Sinai School of Medicine, 79-01 Broadway, Room D3-24C, Elmhurst, NY 11373.

References 

  1. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145–151
  2. Sene D, Piette J, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008;7:272–277
  3. Kupferwasser LI, Haffner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol. 1999;33:1365–1371
  4. Miyakis S, Lockshin MD, Atsumi D, Branch DW, Brey L, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295–306
  5. Levine JS, Ware DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2000;346:752–763
  6. Asherson RA, Cervera R, Piette J, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features in 50 patients. Medicine. 1998;77:195–207
  7. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–1587
  8. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol. 2004;136:393–401
  9. Plein D, Camp GV, Efira A, Bruner A, Vandenbossche J. Intracardiac thrombi associated with antiphospholipid antibodies. J Am Soc Echocardiogr. 1996;9:891–893
  10. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke. 2005;36:592–596
  11. Ziporen L, Goldberg I, Arad M, Hojnik M, Ordi-Ros J, Afek A, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996;5:196–205
  12. Gonzalez-Juanatey C, Gonzalez-Gay MA. Libman-Sacks endocarditis and primary antiphospholipid syndrome. J Heart Valve Dis. 2005;14:700–702
  13. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975;58:243–264
  14. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immumol. 2003;25:79–87
  15. Roman MJ, Shanker B, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399–2406
  16. MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis. 1992;51:152–155
  17. Roldan CA. Valvular and coronary heart disease in systemic inflammatory diseases: systemic disorders in heart disease. Heart. 2008;94:1089–1101
  18. Galve E, Ordi J, Barquinero J, Evangelista A, Vilardell M, Soler-Soler J. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med. 1992;116:293–298
  19. Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus. 2000;9:406–412
  20. Brenner B, Blumenfeld Z, Markiewicz W, Reisner S. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol. 1991;18:931–936
  21. O'Neill D, Magaldi J, Dobkins D, Greco T. Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome. Arch Intern Med. 1995;155:325–327
  22. Agirbasli MA, Hansen DE, Byrd BF. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1997;10:87–88
  23. Qaddoura F, Connolly H, Grogan M, Orszulak TA, Schaff HV, Chandrasekaran K, et al. Valve morphology in antiphospholipid antibody syndrome: echocardiographic features. Echocardiography. 2005;22:255–259
  24. Otto CM. Textbook of clinical echocardiography. 2nd ed. Philadelphia: W.B. Saunders; 2000;342-3
  25. Espinola-Zavaleta NE, Vargas-Barrón J, Colmenares-Galvis T, Cruz-Cruz F, Romero-Carenas A, Keirns C, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J. 1999;137:974–979
  26. Jafar MZ, Morgan MC, Gorscan J. Transesophageal echocardiographic detection of multiple mitral valve masses in primary antiphospholipid syndrome with stroke. Am Heart J. 1994;127:445–446
  27. Silbiger JJ. The valvulopathy of non-bacterial thrombotic endocarditis. J Heart Valve Dis. 2009;18:159–166
  28. Espinola-Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow up study. J Rheumatol. 2004;31:2402–2407
  29. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med. 1993;96:3–9
  30. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997;27:27–35
  31. Weber GV, Fallon J, Silbiger JJ. Hematoma of a congenitally bicuspid aortic valve in a patient with polycythemia vera and the antiphospholipid antibody syndrome. J Am Soc of Echocardiogr. 2006;19:1530;e1-3
  32. Niaz A, Butany J. Antiphospholipid antibody syndrome with involvement of a bioprosthetic heart valve. Can J Cardiol. 1998;14:951–954
  33. Skyrme-Jones RAP, Wardrop CAJ, Wiles CM, Fraser AG. Transesophageal echocardiographic demonstration of resolution of mitral vegetations after warfarin in a patient with the primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1995;8:251–256
  34. Turiel M, Sarzi-Puttini P, Peretti R, Bonizzato S, Muzzapappa S, Atzeni F, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005;96:574–579
  35. Roldan CA, Shively BK, Gurule FT, Smith EA, Crawford MH. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol. 1992;20:1127–1134
  36. Leung W, Wong K, Lau C, Wong C, Liu H. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med. 1990;89:411–419
  37. Roldan CA, Shively BK, Crawford M. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996;19:1424–1430
  38. Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus: association with raised anticardiolipin antibodies. Circulation. 1990;82:369–375
  39. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701–737
  40. Cervera R, Khamashta MZ, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party in systemic lupus erythematosus. Medicine. 1993;72:113–124
  41. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918–3925
  42. Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990;335:1541–1544
  43. Laskin CA, Clark CA, Spitzer KA. Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts?. Rheum Dis Clin North Am. 2005;31:255–272
  44. Urowitz MB, Gladman DD, Tozman ECS, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol. 1984;11:783–787
  45. Yamamato H, Iwade T, Nakano R, Mohri M, Amari Y, Noma M. Numerous small vegetations revealing Libman-sacks endocarditis in catastrophic antiphospholipid syndrome. Circulation. 2007;116:e531–e535
  46. Plastiras SC, Tzelepis GE, Kelekis NL, Vlachoyiannopoulos PG. Catastrophic antiphospholipid syndrome with heart involvement: diagnostic utility of the cardiac MRI. Int J Cardiol. 2007;116:e29–e31
  47. Zakynthinos EG, Vassilakopoulos T, Kontogianni DD, Roussos C, Zakynthinos SG. A role for transesophageal echocardiography in the early diagnosis of catastrophic antiphospholipid syndrome. J Intern Med. 2000;248:519–524
  48. Font R, Cervera C, Pare C, Lopez-Soto A, Palares L, Azqueta M, et al. Non-infective verrucous endocarditis in a patient with “primary” antiphospholipid syndrome. Br J Rheumatol. 1991;30:305–307
  49. Asherson RA, Cervera R. Antiphospholipid antibodies and the heart: lessons and pitfalls for the cardiologist. Circulation. 1991;84:920–923
  50. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J. 1988;60:299–308
  51. Klarich KW, Enriquz-Sarano M, Gura GM, Edwards WD, Tajik AJ, Seward JB. Papillary fibroelastoma: echocardiographic characteristics for diagnosis and pathologic correlation. J Am Coll Cardiol. 1997;30:784–790
  52. Reisner SA, Brenner B, Haim N, Edoute Y, Markiewicz W. Echocardiography in nonbacterial thrombotic endocarditis: from autopsy to clinical entity. J Am Soc Echocardiogr. 2000;13:876–881
  53. Cervera R, Khamashta MA, Font J, Reyes PA, Vianna JL, LoezoSoto A, et al. High prevalence of significant heart valve lesions in patients with the “primary” antiphospholipid syndrome. Lupus. 1991;1:43–47
  54. Reeder GS, Charlesworth JE, Moore SB. Cause of spontaneous echocardiographic contrast as assessed by scanning electron microscopy. J Am Soc Echocardiogr. 1994;7:169–173
  55. Rastegar R, Harnick DJ, Weidemann P, Fuster V, Coller B, Badimon JJ, et al. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol. 2003;41:603–610
  56. Ha J, Chung N, Kang S, Jang K, Kim I, Rim S, et al. Enhanced detection of left atrial spontaneous echo contrast by transthoracic harmonic imaging in mitral stenosis. J Am Soc Echocardiogr. 1995;13:849–854
  57. Espinosa G, Cervera R, Font J. Cardiac and pulmonary manifestations in the antiphospholipid syndrome. The antiphospholipid syndrome II: autoimmune thrombosis. New York: Elsevier Science; 2002;169-88
  58. Gundogdu F, Unlu Y, Baris N, Arslan S. Antiphospholipid antibody syndrome leading to massive pulmonary embolism and sudden death. Arch Turk Soc Cardiol. 2008;36:467–469
  59. Ye Z, Yu W, Hsueh C, Leu H, Chen J, Lin S. Antiphospholipid syndrome presenting as intracardiac thrombus with pulmonary embolism. Circ J. 2005;69:1290–1292
  60. Tenedios F, Erkan D, Lockshin MD. Cardiac manifestations in the antiphospholpid syndrome. Rheum Dis Clin North Am. 2006;32:491–507
  61. Espinosa G, Cervera R, Font J, Asherson RA. The lung in antiphospholipid syndrome. Ann Rheum Dis. 2002;61:95–98
  62. Weng C, Cheng L, Wang C. Pulmonary infarctions due to bilateral pulmonary arterial thrombosis in a lupus patient with antiphospholipid syndrome. J Rheumatol. 2008;35:2064–2065
  63. Sagie A, Schwammenthal E, Padial LR, Vazquez de Prada JA, Weyman AE, Levine RA. Determinants of functional tricuspid regurgitation in incomplete tricuspid closure: Doppler color flow study of 109 patients. J Am Coll Cardiol. 1994;24:446–453
  64. Duman D, Demirtunc R, Duman D, Sungur F, Agirbasli M, Cakmak M. Paradoxical mesentery embolism and silent myocardial infarction in primary antiphospholipid syndrome. Heart Surg Forum. 2006;9:e592–e594
  65. Ogimoto A, Sekiya M, Funada J, Miyagwa M, Kubo Y, Akutsu H. Antiphospholipid syndrome with acute myocardial infarction and portal vein thrombosis. Jpn Circ J. 2000;64:468–470
  66. Badak O, Guneri S, Kirimili O, Goldeli O, Aslan O, Ozsan H. Primary stenting in a patient with acute myocardial infarction and primary antiphospholipid syndrome. J Invasive Cardiol. 2002;14:194–197
  67. Korkmaz C, Cansu DU, Kasifoglu T. Myocardial infarction in young patients with systemic lupus erythematosus: a case report and clinical analysis of the literature. Lupus. 2007;16:289–297
  68. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turieil M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14:683–686
  69. Lim BA. Tako Tsubo cardiomyopathy in a patient with antiphosphplipid syndrome secondary to systemic lupus erythematosus. Med J Malaysia. 2008;63:146–147
  70. Coudray N, de Zittere D, Bletry O, Piette J, Wechsler B, Godeau P, et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J. 1995;74:531–535
  71. Hasnie AMA, Stoddard MF, Gleason CB, Wagner SG, Longaker RA, Pierangeli S, et al. Diastolic dysfunction is a feature of the antiphospholipid syndrome. Am Heart J. 1995;129:1009–1013
  72. Paran D, Caspi D, Levartovsky Elkayam O, Kaufman I, Litinsky I, et al. Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2007;66:506–510
  73. Cypiene A, Kovaite M, Dadoniene J, Dadoniene J, Rugiene R, Petrulioniene Z, et al. Arterial wall dysfunction in systemic lupus erythematosus. Lupus. 2009;18:522–529
  74. Chow P, Ho MH, Lee T, Lau Y, Cheung Y. Relation of arterial stiffness to left ventricular structure and function in adolescents and young adults with pediatric-onset systemic lupus erythematosus. J Rheumatol. 2007;34:1345–1352
  75. Leite-Moreira AF, Correia-Pinto J, Gillbert TC. Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res. 1999;43:344–353
  76. Menzel T, Wagner S, Kramm T, Mohr-Kahaly S, Mayer E, Braeuninger S, et al. Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension. Chest. 2000;118:897–903
  77. Gurduvan SV, Malouf PJ, Auger WR, Waltman TJ, Madani M, Raisinghani AB, et al. Abnormal left ventricular filling in chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2007;48:1334–1339
  78. Tektonidou MG, Ioannidis JPA, Moyssakis I, Boki KA, Vassiliou BK, Vlachoyiannopoulos PG, et al. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. Ann Rheum Dis. 2001;60:43–48

PII: S0894-7317(09)00622-1

doi: 10.1016/j.echo.2009.06.023

Journal of the American Society of Echocardiography
Volume 22, Issue 10 , Pages 1100-1108 , October 2009

Article Tools

* Image Usage & Resolution